Financial health
- Operating income covered interest expense -13.5× in the latest year.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$71M | — | — | — | — | $7M |
| 2024 | — | -$74M | — | — | -$56M | — | $9M |
| 2023 | — | -$156M | — | — | -$103M | — | $9M |
| 2022 | — | -$223M | — | — | -$265M | — | $44M |
| 2021 | $0 | -$157M | — | — | -$180M | — | $38M |
| 2020 | $138000 | -$38M | 0.0% | -24379.7% | -$80M | — | $242M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$4M | — | — | — | — | $5M |
| Dec '25 | — | -$8M | — | — | — | — | $7M |
| Sep '25 | — | -$14M | — | — | — | — | $6M |
| Jun '25 | — | -$21M | — | — | — | — | $8M |
| Mar '25 | — | -$28M | — | — | — | — | $15M |
| Dec '24 | — | -$12M | — | — | -$11M | — | $9M |
| Sep '24 | — | -$23M | — | — | -$20M | — | $7M |
| Jun '24 | — | -$15M | — | — | -$11M | — | $7M |
| Mar '24 | — | -$24M | — | — | -$14M | — | $5M |
| Dec '23 | — | -$13M | — | — | -$13M | — | $9M |
| Sep '23 | — | -$67M | — | — | -$20M | — | $9M |
| Jun '23 | — | -$19M | — | — | -$27M | — | $22M |
| Mar '23 | — | -$57M | — | — | -$43M | — | $27M |
| Dec '22 | — | -$54M | — | — | -$50M | — | $44M |
| Sep '22 | — | -$56M | — | — | -$66M | — | $41M |
| Jun '22 | — | -$59M | — | — | -$73M | — | $42M |
| Mar '22 | — | -$54M | — | — | -$75M | — | $61M |
| Dec '21 | $0 | -$55M | — | — | -$61M | — | $38M |
| Sep '21 | $0 | -$43M | — | — | -$51M | — | $20M |
| Jun '21 | $0 | -$35M | — | — | -$41M | — | $567M |
See the revenue and net-income charts above for Instil Bio, Inc.'s multi-year trend.
As of FY2025, Instil Bio, Inc. reported — of total debt against $7M of cash; operating income covered interest expense -13.5×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.